Celltrion is doing well in Japan, recording the top market share for cancer and rheumatoid arthritis drugs

In November, pharmaceutical company Celltrion's biosimilar breast and stomach cancer drug "Hojuma" (the active ingredient is trastuzumab) rose to 74% of the market share in Japan.